用科技之精确，证验传统之精深。通过构建现代化创新体系，研发团队进一步对《伤寒论》《金匮要 略》等经典典籍中的方剂进行转化研究，运用现代组学技术深度解析，搭建起拥有12万条古方数据的知 识图谱，并借助AI算法挖掘潜在功效成分群，提升古代经典名方转化率，远超行业平均水平。与此同 时，针对中药复杂成分体系的质控难题，康缘药业首创"功效成分群"质控体系，采用"化学指纹图谱— 生物活性评价—临床疗效验证"三位一体评价模型，将质控指标从传统的3—5个大幅提升到动态监测的 30—50个功效成分群，进而形成一套完善的质控体系。 秉持"让中药回归到药物自身属性——安全、有效、质量均一"的研发理念，康缘药业以临床价值为导 向，聚焦病毒性感染性疾病、妇科疾病等中医药优势领域，打造系统完善的全流程研发平台，目前拥有 59个中药新药，近五年累计获批6个中药新药，获批中药创新药总数位居行业之首。其中，筋骨止痛凝 胶是近十年来首个上市的中药凝胶剂；银翘清热片是2020年新药品注册管理办法实施后首个获批的1.1 类创新中药；苓桂术甘颗粒则是首个按古代经典名方目录管理的3.1类中药新药，入选2022年度中医药 十大学术进展。 苓桂术甘汤、四逆 ...

Core Insights - Shandong Buchang Pharmaceutical has been recognized as an "Advanced Intelligent Factory" by the Shandong Provincial Department of Industry and Information Technology for its systematic intelligent manufacturing practices [1][2] - The factory integrates traditional Chinese medicine with modern technology through a comprehensive digital transformation across five major processes and 14 scenarios, promoting a shift towards new productive forces in the Chinese medicine industry [1] Company Developments - Buchang Pharmaceutical has achieved several technological breakthroughs addressing key pain points in intelligent manufacturing of traditional Chinese medicine, including precise material delivery, continuous production, and intelligent drying technologies [1] - The implementation of these technologies has resulted in a 40% reduction in energy consumption and a doubling of production efficiency [1] - The factory's annual production capacity for its core product, Xinxin Granules, has surpassed 5 billion bags, serving over 10 million patients daily [1] Industry Impact - The establishment of a digital traceability system covering 350 nodes for Chinese medicinal herb cultivation, along with 345 standardized planting techniques, has led to over 5,000 farmers experiencing an annual income increase of more than 30% [1] - The intelligent factory currently holds 473 patents and focuses on intelligent equipment, continuous pharmaceutical production, resource conservation, and green engineering to promote the inheritance and innovation of traditional Chinese medicine [1][2]

Core Viewpoint - Jiangsu Kangyuan Pharmaceutical's invention patent for a method and system for detecting the total solid content in traditional Chinese medicine (TCM) formulations has gained attention for its innovative use of refractive index technology, enabling rapid and precise quality control in TCM production [1][2][4] Group 1: Traditional Detection Challenges - Traditional methods for measuring total solid content in TCM are time-consuming, often taking half a day to complete, and can damage samples, leading to waste [1] - The industry faces challenges with slow detection speeds that hinder the efficiency of smart manufacturing processes [1] Group 2: Innovative Detection Technology - The research team at Kangyuan Pharmaceutical developed a non-destructive detection technology based on a refractive index-total solid content correlation model, achieving rapid and accurate measurements [2] - The model has been successfully validated in major products like Heat Toxicity Ning injection and Jin Zhen oral liquid, with prediction errors below 10%, demonstrating its reliability [2] Group 3: Benefits of the New Technology - The new detection method reduces processing time from hours to seconds, significantly improving production efficiency [4] - It saves over one million yuan annually in raw material costs by preventing sample destruction [4] - The technology enhances reliability compared to manual detection, with continuous self-optimization of the model [4] Group 4: Industry Impact - The introduction of refractive index technology represents a significant innovation in quality control for the TCM industry, setting a new standard for intelligent manufacturing [4] - Kangyuan Pharmaceutical plans to expand the application of this technology to more TCM products, potentially impacting the quality of every oral liquid and capsule received by patients [4]